Navigation Links
HHS Buys Next Generation Smallpox Vaccine

WASHINGTON, HHS Secretary Mike Leavitt announced today that HHS has awarded a contract for $500 million to Bavarian Nordic A/S of Copenhagen, Denmark to manufacture and deliver 20 million doses of a next generation modified vaccinia Ankara (MVA) smallpox vaccine.

The vaccine would be recommended in the event of a smallpox outbreak to protect people in the United States who have weakened immune systems. The full supply of the vaccine will be added to the Strategic National Stockpile, a reserve of large quantities of medicine and medical supplies to protect the American public if there is a public health emergency.

"To protect ourselves from the remote but extremely grave threat of a deliberate release of smallpox virus, we need vaccines that can be safely given to all Americans, including individuals with weakened immune systems," Secretary Leavitt said. "Acquiring a stockpile of this new smallpox vaccine is a key step toward protecting even more members of the American public against a smallpox release."

As part of HHS' comprehensive strategy to address the public health threat of a smallpox outbreak, the Strategic National Stockpile currently contains sufficient smallpox vaccine for every American. However, that vaccine supply was produced using vaccinia virus, a relative of smallpox virus. A live, replicating virus, vaccinia can cause side effects which, on rare occasions, can be potentially life-threatening. People with compromised immune systems, such as patients on chemotherapy or people with HIV/AIDS should not receive live, replicating smallpox vaccines in non-emergency situations.

The MVA smallpox vaccine contains a highly weakened form of the vaccinia virus that cannot replicate in humans. The MVA vaccine could be used in immunocompromised individuals, of whom there are an estimated 10 million in the U.S. In the event of a possible smallpox outbreak, the 20 million doses (the vaccine is being tested w ith a two-dose immunization schedule) of MVA vaccine purchased under this contract would be available to them.

This is the first BioShield contract to allow two types of advance (pre-delivery) payments -- one under the Project BioShield Act of 2004, and the other under the Pandemic and All-Hazards Preparedness Act of 2006. The contract also is the first under the Pandemic and All-Hazards Preparedness Act.

Under BioShield, the company can get an advance payment based on a determination that it is necessary to the success of the product. Under the Pandemic and All-Hazards Preparedness Act, the company can get payments as it reaches certain milestones in product development, before delivery of product to the Strategic National Stockpile.

"The use of these new authorities under the Pandemic and All-Hazards Preparedness Act further demonstrates our commitment to building improved partnerships with industry," Secretary Leavitt said.

This procurement builds upon the MVA smallpox vaccine research and development efforts initiated by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

Through research funded by NIAID in 2003, scientists successfully performed small-scale manufacturing of the MVA vaccines and conducted Phase I clinical trials in healthy volunteers. These early development studies showed that MVA vaccine was safe and was able to stimulate an immune response in healthy volunteers. Large-scale manufacturing of the vaccine was subsequently performed. Several Phase II clinical studies are now either under way or planned, in healthy individuals and in individuals with weakened immune systems. The purpose of these studies is to further assess the safety of the vaccine, and also to begin to assess how effective the vaccine will be based on the immune responses generated.

The last case of smallpox occurred in the United States in 1949 , and the disease was declared eradicated worldwide in 1980 by the World Health Organization (WHO). However, there is concern that if terrorists obtained the virus, they could develop it as a weapon. Vaccinations to prevent smallpox have not been routinely administered in the United States since 1972, and people vaccinated prior to 1972 very likely have diminished immunity to smallpox.


'"/>




Related medicine news :

1. Hearing Problems Of Middle Age Are Affecting The Younger Generation
2. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
3. Newer Generation Sleeping Pills Lack Superior Performance
4. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
5. Moles Among The Older Generation May Be Dangerous
6. Leptin, The Next Generation Antidepressant?
7. Generation Scotland To Examine Relation Between Lifestyle, Genetics and Health
8. Baby Gloom: ‘Baby Gap’ Generation Signals Babies’ Days Ot!
9. Researchers Aim To Develop Next Generation Of Surgical Robots
10. New Generation Teenagers Addiction to Prescription Drugs
11. New Generation - Medicinal Products
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff ... located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, ... treatment for a brain tumor. , Jason Bauer and his family are longtime ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
Breaking Medicine Technology: